Please assess the completion status of the following clinical trial:

Trial Title: Study of IMC-1121B in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Solid tumor participant who was been histopathologically or cytologically documented.~* Advanced primary or recurrent solid tumors participant who has not responded to standard therapy or no standard therapy is available.~* The participant has measurable or nonmeasurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST).~* The participant has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 at study entry.~* The participant is able to provide written informed consent.~* The participant is age 20 years or older.~* The participant has a life expectancy of \> 3 months.~* The participant has adequate hematologic function, as defined by:~* An absolute neutrophil count (ANC) \> 1500/cubic millimeter (mm³) or /microliter (µL)~* A hemoglobin level \> 10 grams/deciliter (g/dL)~* A platelet count \> 100,000/mm³ or /µL~* The participant has adequate hepatic function, as defined by:~* A total bilirubin level \< 1.8 milligrams/deciliter (mg/dL)~* Aspartate transaminase (AST) levels \< 86 International Units/liter (IU/L)~* Alanine transaminase (ALT) levels ≤ 86 IU/L~* The participant has adequate renal function, as defined by:~* Serum creatinine level ≤ 1.5 mg/dL, or~* Calculated serum creatinine clearance (Cockcroft-Gault) ≥ 60 milliliters/minute (mL/min)~* The participant's urinary protein is 0 on dipstick or 1+ but participant does not have edema nor serum albumin \< lower level of normal (LLN).~* The participant has adequate coagulation function, as defined by international normalized ratio (INR) ≤ 1.5.~* The participant agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study treatment.~Exclusion Criteria:~* The participant has had chemotherapy or therapeutic radiotherapy within 28 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or participant has ongoing side effects ≥ Grade 2 due to agents administered more than 28 days earlier.~* The participant has obvious evidence of intratumor cavitation.~* The participant has undergone major surgery (example, laparotomy, thoracotomy, removal of organ\[s\]) within 28 days prior to study entry, or subcutaneous venous access device placement within 7 days prior to study entry.~* The participant has a history of postoperative bleeding complications or wound complications from a surgical procedure.~* The participant has elective or planned surgery to be conducted during the trial.~* The participant has documented and/or symptomatic brain or leptomeningeal metastases. (Participants who are clinically stable \[no symptoms during 4 weeks prior to the enrollment\] with an assessment that no further treatment \[radiation, surgical excision, and administration of steroids\] is required, are permitted to enter the study.)~* The participant has uncontrolled intercurrent illness including, but not limited to:~* Thrombotic or hemorrhagic disorders~* Hemoptysis (approximately one-half of a teaspoon)~* Ongoing or active infection requiring systemic antibiotic treatment~* Congestive heart failure (Class III or IV of the New York Heart Association classification for heart disease)~* Angina pectoris, angioplasty, stenting, or myocardial infarction within 6 months~* Uncontrolled hypertension (systolic blood pressure \> 150 millimeters of mercury (mmHg), diastolic blood pressure \> 95 mm Hg)~* Cardiac arrhythmia requires treatment \[National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v 3.0), Grade 3\], or asymptomatic sustained ventricular tachycardia)~* Peripheral neuropathy of any etiology ≥ Grade 2 (NCI-CTCAE v 3.0)~* The participant has participated in clinical studies of non-approved experimental agents or procedures within 4 weeks prior to study entry for small molecules, or 8 weeks prior to study entry for non-approved monoclonal antibodies.~* The participant, if female, is pregnant (confirmed by urine or serum pregnancy test) or lactating.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMC-1121B (Type: EXPERIMENTAL): Participants receiving IMC-1121B intravenously

Based on this trial design, predict the completion outcome and termination type (if applicable).